Rokit Healthcare FY 2025 Annual Report
Beta

Filed: March 23, 2026· period ending December 31, 2025DART

Rokit Healthcare annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).

Rokit Healthcare FY 2025 Annual Report Analysis

Business Overview

• AI personalized long-term regeneration platform combining 3D bioprinter, disposable medical kits, and bioink for chronic wounds, cartilage, kidney regeneration, FY2025
• Dr. INVIVO AI Regen Kit received MFDS Class 3 approval Jan 2023, USFDA Class I/II registration Feb 2023, and EU CE MDR Class IIa July 2023

Management Discussion & Analysis

• No specific financial figures disclosed for FY2025 revenue, operating profit, or net income in the MD&A section
• No segment-level performance attribution or key business driver described for FY2025 in the management narrative

Risk Factors

• USD foreign exchange exposure sensitivity ±KRW 464M pre-tax for 10% KRW/USD fluctuation at FY2025 year-end
• Interest-bearing debt with variable rate KRW 2.88B; 1% interest rate change impacts profit/loss by ±KRW 28.8M

Rokit Healthcare FY 2025 Key Financial Metrics
DART

Total Assets

KRW 55.0B

▲ +385.7% YoY

Operating Cash Flow

-KRW 17.2B

▼ -244.4% YoY

CapEx

KRW 163.3M

▲ +698.8% YoY

Source: KIFRS consolidated financial data from Rokit Healthcare annual report on DART. All figures in KRW.

Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding